Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates
- 1 December 2011
- journal article
- research article
- Published by Elsevier
- Vol. 64 (12) , 1412-1417
- https://doi.org/10.1016/j.jclinepi.2011.06.011
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Cost-Effectiveness of Prostate Specific Antigen Screening in the United States: Extrapolating From the European Study of Screening for Prostate CancerJournal of Urology, 2011
- What Is the True Number Needed to Screen and Treat to Save a Life With Prostate-Specific Antigen Testing?Journal of Clinical Oncology, 2011
- Comorbidity and Mortality Results From a Randomized Prostate Cancer Screening TrialJournal of Clinical Oncology, 2011
- Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening TrialClinical Trials, 2010
- Prostate Cancer Diagnosis and Treatment After the Introduction of Prostate-Specific Antigen Screening: 1986-2005JNCI Journal of the National Cancer Institute, 2009
- Mortality Results from a Randomized Prostate-Cancer Screening TrialNew England Journal of Medicine, 2009
- Screening and Prostate-Cancer Mortality in a Randomized European StudyNew England Journal of Medicine, 2009
- Lead Time and Overdiagnosis in Prostate-Specific Antigen Screening: Importance of Methods and ContextJNCI Journal of the National Cancer Institute, 2009
- Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–99: results of the EUROCARE-4 studyThe Lancet Oncology, 2007
- Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview SurveyCancer, 2007